Post by
enriquesuave on May 03, 2024 1:31pm
CGON 35% 12 months CR?
Looks like they just presented data and from what I understand 29 out of 83 patients have maintained. They treated 105 patients and 75% have achieved a CR at anytime. 22 patients are still pending data at 12 months. So 29 out of 83 so far = 34.9% CR at 12 months. Seems like we are beating them badly. IMHO time will tell . Will we hit $4 USD Billion MC like them when we get BTD?
Comment by
Eoganacht on May 03, 2024 2:36pm
Yes it looks like 34.9% CRR at 12 months. And this is down to 20% CRR at 21 months ! Here is a link to their presentation: Pivotal Results from BOND-003 The results and swimmers plot are on slide 8. 6 month DOR = 52 out of 97 patients = 54% 12 month DOR = 29 out of 83 patients= 34.9% 21 months DOR = 14 out of 69 patients = 20%
Comment by
enriquesuave on May 03, 2024 3:34pm
Nice find! We are killing them in our durable and longer term data data it seems so far! IMHO
Comment by
Eoganacht on May 03, 2024 4:06pm
At AUA 2025 Theralase will probably give a similar presentation except that the number of treatments will be 2 or 3 rather than 18 - 24 and the 24 month CRR will be greater than 30% rather than 20% IMHO
Comment by
enriquesuave on May 03, 2024 4:20pm
By then we will also have hit a $5 Billion USD MC like our competitors! Hopefully
Comment by
Alamir1111 on May 03, 2024 4:42pm
Min.10 bill is the asking price
Comment by
Alamir1111 on May 03, 2024 5:01pm
Market estimate for pain dementia viruses cancer etc is about 500 bill or more 10% of that is??
Comment by
Yajne on May 03, 2024 5:03pm
Thanks for posting Eogan! I also found slide 16 "collaborators" interesting, includes some familiar names...Peter Black (UBC), Neal Shore (Carolina), Ashish Kamat (MD Anderson). With multiple trials happening for these guys, I always wonder how much priority Ruvidar gets at its clinical study sites
Comment by
Alamir1111 on May 03, 2024 6:16pm
Interesting would be to see the numbers each facility treated ??
Comment by
StevenBirch on May 03, 2024 6:36pm
It seems as if you're almost waiting in line with so many ongoing trials, let's hope TLT is next in line! Maybe these perceived 'delays' have nothing to do with TLT, that may upset some people.
Comment by
toade1313 on May 03, 2024 7:34pm
Even assuming the delays have nothing to do with TLT, the reason(s) for the delay should be communicated by TLT management.
Comment by
stocksnbonds458 on May 06, 2024 8:48am
Very true Toade, it's very close to 1 year now since the FDA asked for some clarification on TLT data submitted as part of the Pre-BTD application. In fact, it was last June, so next month is 1 year!! ALL Shareholders deserve a VERY detailed explanation.